Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.

In contrast, remdesivir use showed a trend to lower mortality risk (aHR, 0.48; 95% CI, 0.23–1.02) ( Figure 1 ).

also in 53,322 other papers

Thereafter, all of them showed a decreasing trend with minor differences in the trajectories between treatment groups and initial small and transient increases in the levels of IL-6 and D-dimer ( Figure 4 ).

also in 47,180 other papers